Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.69 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011508 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL245340 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL28005458 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15011361 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL29575947 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL3609223 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15286633 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL2612405 | 1.00 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15282062 | 0.98 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15058586 | 0.98 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110157766-B | Preparation method of (1R,2S) -2- (3, 4-difluorophenyl) cyclopropylamine | 浙江科技学院 | 2021-03-26 | — | — | CN | claimed |
| CN-110157766-A | The preparation method of one kind (1R, 2S) -2- (3,4- difluorophenyl) cyclopropylamine | 浙江科技学院 | 2019-08-23 | — | — | CN | claimed |
| CN-109485575-A | A kind of preparation method of ticagrelor chiral intermediate | 苏州特瑞药业有限公司 | 2019-03-19 | — | — | CN | claimed |
| CN-103242171-A | Method for preparing trans-(1R,2S)-2-(3,4-difluorophenyl) cyclopropylamine | SUZHOU MINGRUI MEDICAL TECHNOLOGY CO LTD | 2013-08-14 | — | — | CN | claimed |
| US-20120130097-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | US | claimed |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2011-08-04 | — | — | US | claimed |
| CN-115894496-B | Preparation method of ticagrelor and intermediate thereof | 上海贝美医药科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-117164465-A | Phenyl cyclopropylamine compound and preparation method and application thereof | 郑州大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322784-A1 | Process for the Preparation of Ticagrelor | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2023-10-12 | — | — | US | disclosed |
| CN-116410946-A | Carbonyl reductase LsCR mutant and application thereof in catalytic synthesis of chiral alcohol | 浙江工业大学 | 2023-07-11 | — | — | CN | disclosed |
| EP-4161932-A1 | PROCESS FOR THE PREPARATION OF TICAGRELOR | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2023-04-12 | — | — | EP | disclosed |
| CN-115894496-A | Preparation method of ticagrelor and intermediate thereof | 上海贝美医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| WO-2008018823-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| US-7122695-B2 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-7067663-B2 | Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-0996621-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999005143-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | KDM1A 4171/4885KDM1B 4072/4885KCNH2 3540/4885 |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
| US-20230322784-A1 | Process for the Preparation of Ticagrelor | TH, NT5C, P2RY6 | KDM1A 2022/4885KDM1B 2868/4885KCNH2 2405/4885 |
| US-20120130097-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES | MCCC2, DHPS, CYP3A4 | KDM1A 2952/4885KDM1B 2629/4885KCNH2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.